Amino acid imbalance in patients with chronic liver diseases

Hepatology Research

Volumn 40, Issue 4, 2010, Pages 393-398

  Michitaka, Kojiro ^a   Hiraoka, Atsushi ^a   Kume, Misaki ^a   Uehara, Takahide ^a   Hidaka, Satoshi ^a   Ninomiya, Tomoyuki ^a   Hasebe, Aki ^a   Miyamoto, Yasunao ^a   Ichiryu, Misa ^a   Tanihira, Tetsuya ^a   Nakahara, Hiromasa ^a   Ochi, Hironori ^a   Tanabe, Atsushi ^a   Uesugi, Kazuhiro ^b   Tokumoto, Yoshio ^b   Mashiba, Toshie ^b   Abe, Masanori ^b   Hiasa, Yoichi ^b   Matsuura, Bunzo ^b   Onji, Morikazu ^b  

^a EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Branched chain amino acids; Branched chain amino acids to tyrosine level ratio; Chronic hepatitis; Liver cirrhosis; Tyrosine

Indexed keywords

BRANCHED CHAIN AMINO ACID; TYROSINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINOACIDOPATHY; ARTICLE; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 77954355548     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00614.x     Document Type: Article

References (41)

1. Munro HN, Fernstrom JD, Wurtman RJ. Insulin, plasma amino acid imbalance, and hepatic coma. Lancet 1975, 1:722-4.
2. Fischer JE, Funovics JM, Aguirre A. The role of plasma amino acids in hepatic encephalopathy. Surgery 1975, 78:276-90.
3. James JH, Escourrou J, Fischer JE. Blood-brain neutral amino acid transport activity is increased after portacaval anastomosis. Science 1978, 200:1395-7.
4. Rossi-Fanelli F, Angelico M, Cangiano C. Effect of glucose and/or branched chain amino acid infusion on plasma amino acid imbalance in chronic liver failure. JPEN J Parenter Enteral Nutr 1981, 5:414-19.
5. Oster JR, Perez GO. Acid-base disturbances in liver disease. J Hepatol 1986, 2:299-306.
6. Soeters PB, Fischer JE. Insulin, glucagon, amino acid imbalance, and hepatic encephalopathy. Lancet 1976, ii:880-2.
7. James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy. Lancet 1979, 2:772-5.
8. Fischer JE. Branched-chain-enriched amino acid solutions in patients with liver failure: an early example of nutritional pharmacology. JPEN J Parenter Enteral Nutr 1990, 14:249S-56S.
9. Sugiyama M, Kanno T, Ohkubo A, Muto Y, Murata K, Ueno Y. The clinical usefulness of the molar ratio of branched-chain amino acids to Tyrosine (BTR) in discriminating stage of chronic liver diseases. Jpn J Clin Pathol 1992, 40:673-8. In Japanese, Abstract in English
10. Suzuki K, Suzuki K, Koizumi K. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. Hepatol Res 2008, 38:267-72.
11. Ninomiya T, Yoon S, Sugano M. Improvement of molar ratio of branched-chain amino acids to tyrosine (BTR) associated with liver fibrosis in chronic hepatitis C patients treated with interferon-alpha. Dig Dis Sci 1999, 44(5):1027-33.
12. Desmet VJ, Gerber M, Hoofnagle JH. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-20.
13. Blei AT, Cordoba J. Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001, 96:1968-76.
14. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-21. The Member of the Working Party
15. Ong JP, Aggarwal A, Krieger D. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003, 114:188-93.
16. Rose C, Butterworth RF, Zayed J. Manganese deposition in basal ganglia structures results from both portalsystemic shunting and liver dysfunction. Gastroenterology 1999, 117:640-4.
17. Giewekemeyer K, Berding G, Ahl B, Ennen JC, Weissenborn K. Bradykinesia in cirrhotic patients with early hepatic encephalopathy is related to a decreased glucose uptake of frontomesial cortical areas relevant for movement initiation. J Hepatol 2007, 46:1034-9.
18. Dejong CHC, van de Poll MCG, Soeters PB, Jalan R, Damink SO. Aromatic amino acid metabolism during liver failure. J Nutr 2007, 137:1579S-85S.
19. Kato A, Kato M, Ishii H. Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria - multicenter collaborative study in Japanese. Hepatol Res 2004, 30:71-8.
20. Kircheis G, Fleig WE, Gortelmeyer R, Grafe S, Haussinger D. Assessment of low-grade hepatic encephalopathy: a critical analysis. J Hepatol 2007, 47:642-50.
21. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-66.
22. Romero-Gomez M, Cordoba J, Jover R. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007, 45:879-85.
23. Geissler A, Lock G, Frund R. Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997, 25:48-54.
24. Laubenberger J, Haussinger D, Bayer S, Gufler H, Hennig J, Langer M. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997, 112:1610-16.
25. Michitaka K, Tokumoto Y, Uesugi K. Neuropsychiatric dysfunction in patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2008, 38:1069-75.
26. Fontana RJ, Bieliauskas LA, Back-Madruga C. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005, 43:614-22.
27. McAndrews MP, Farcnik K, Carlen P. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005, 41:801-8.
28. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002, 35:440-6.
29. Groeneweg M, Quero JC, Bruijn ID. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28:45-9.
30. Bajaj JS, Hafeezullah M, Hoffmann RG. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology 2008, 47:596-604.
31. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001, 96:2718-23.
32. Amodio P, Del Piccolo F, Marchetti P. Clinical features and survival of cirrhotic patients with subclinical cognitive alternations detected by the number connection test and computer psychometric tests. Hepatology 1999, 29:1662-7.
33. Watanabe A, Sakai T, Sato S. Clinical efficacy of lactulose in patients with and without subclinical hepatic encephalopathy. Hepatology 1997, 26:1410-14.
34. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-59.
35. Bajaj JS, Saeian K, Christensen KM. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-15.
36. Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G. Overview of randomized clinical trials of oral branchedchain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996, 20:159-64.
37. Nakaya Y, Okita K, Suzuki K. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007, 23:113-20.
38. Aoyama K, Tsuchiya M, Mori K. Effect of a late evening snack on outpatients with liver cirrhosis. Hepatol Res 2007, 37:608-14.
39. Muto Y, Sato S, Watanabe A. Effects of oral branchedchain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
40. Urata Y, Okita K, Korenaga K, Uchida K, Yamasaki T, Sakaida I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res 2007, 37:510-16.
41. Kobayashi M, Ikeda K, Arase Y. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 2008, 43:63-70.